Christer Ahlberg interviewed by Redeye about the Q2 report and HEEALING1
Christer Ahlberg, CEO of Cinclus Pharma, spoke with Kevin Sule at Redeye about the company’s Interim Report for the Second Quarter of 2026 and the ongoing Phase III trial, HEEALING1.